Karo Pharma receives approval to delist the Company’s share from Nasdaq Stockholm in connection with the change of listing venue to Nasdaq First North Growth Market
Karo Pharma Aktiebolag (publ) (the “Company” or ”Karo Pharma”) announced in a press release on 9 March 2022 that Karo Pharma’s Board of Directors has decided to apply for delisting of the Company’s share from Nasdaq Stockholm as well as listing on Nasdaq Stockholm First North Growth Market, and that the application on delisting had been submitted to Nasdaq Stockholm. Today, the Company has received approval of delisting of the Company’s share from Nasdaq Stockholm. Nasdaq Stockholm’s approval is conditional on Karo Pharma’s share being approved for admission to trading on Nasdaq First North